Navigation Links
Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
Date:8/30/2007

WASHINGTON, Aug. 30 /PRNewswire/ -- Prestwick Pharmaceuticals, Inc., a privately-held biotechnology company, today announced that it has hired Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer.

Dr. Stogniew will be responsible for Prestwick's pre-clinical development, regulatory and patent activities around its portfolio of products including its lead product candidate, tetrabenazine, a highly selective and reversible dopamine depletor in Phase 3 clinical trials for potential use as a treatment for chorea associated with Huntington's Disease.

He joins Prestwick most recently from Zelos Therapeutics, where he was Executive Vice President of Development responsible for pre-clinical, regulatory and patent development.

"With 25 years focused on developing drugs and 25 patents to his name, Marty will immediately help Prestwick as we work to execute and enhance our pipeline," said George F. Horner III, President and Chief Executive Officer of Prestwick. "He has made a significant impact in the development of successful drugs such as Anidulafugin, Amifostine and Idarubicin -- all of which are now on the market and positively impacting patients' lives."

Dr. Stogniew worked with Mr. Horner at Vicuron Pharmaceuticals, Inc. as Executive Vice President of Scientific Affairs from 2001 to 2005 before Vicuron was purchased by Pfizer in 2005 for $1.9 billion. Prior to Vicuron, Dr. Stogniew served as Chief Scientific Officer at Next Pharmaceuticals, Inc. and as Vice President of Pharmaceutical Sciences at MedImmune. Dr. Stogniew holds a Ph.D. in Medicinal Chemistry and a B.S. in Pharmacy from the University of Maryland.

About Prestwick

Prestwick is currently managing a portfolio of pipeline product candidates being studied for CNS conditions with significant unmet needs, including Huntington's disease, Parkinson's disease, restless legs syndrome, schizophrenia, autism, Alzheimer's disease and sleep apnea.

Pl
'/>"/>

SOURCE Prestwick Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Traveling stem cell show continues state tour
2. AT&T - BellSouth merger: Revestiture continues
3. Madison biotech continues its climb
4. Brady continues growth through Asian acquisition
5. Transition continues to impact Third Wave financials
6. Line between big pharma, big biotech continues to blur
7. Wisconsin giant continues to dominate the health care IT market
8. API Software continues expansion
9. Third Wave continues molecular diagnostic focus with new CEO
10. Midwest Public-Sector Biotech Continues to Sizzle
11. Corona Optical Systems continues to excite investors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/17/2010)... BALTIMORE , March 17 Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a ... the value of oncology drugs, today announced its financial results for the third  fiscal quarter ... the Company,s Form 10-Q at www.championsbiotechnology.com . , ... ...
(Date:3/17/2010)... ( AEZS, TSX: AEZ) (the "Company"), a late-stage drug development company specialized in ... and operating results before market open on Wednesday, March 24, 2010 . ... later that same day at 10:00 a.m., Eastern Time . , ... ...
(Date:3/17/2010)... ... on Stereomicroscopy and Converting to 3D Imaging , ... Thornwood, N.Y. (PRWEB) March 17, 2010 -- Carl Zeiss, ... and industrial applications, recently announced two exciting online promotions. For a limited time, and ...
(Date:3/16/2010)... 16, 2010)Pancreatic cancerknown as the most fatal cancer with ... promising approach may come in the form of tiny ... a novel procedure called "nanoembolization," said researchers at the ... Tampa, Fla. , "As current treatments for pancreatic cancer ...
Breaking Biology Technology:Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results 2Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results 3Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results 4Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results 5Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results 6Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results 7Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results 8Æterna Zentaris to Announce Fourth Quarter Full Year 2009 Financial and Operating Results on March 24, 2010 2Carl Zeiss Offers Online Promotions 2Going for gold with a novel interventional radiology treatment for pancreatic cancer 2Going for gold with a novel interventional radiology treatment for pancreatic cancer 3
... Inc. (Amex: IMA ) today announced that ... Conference on Tuesday, August 12, 2008,at the InterContinental ... is scheduled to present at 4:30 pm and ... through a webcast accessible at, http://www.corporateir.net/ireye/conflobby.zhtml?ticker=IMA&item_id=1887690 , as ...
... Fiscal Year service revenue grows approximately 33% ... - Operating margin ... the ... BOSTON, Aug. 6 PAREXEL International,Corporation (Nasdaq: PRXL ) today announced its financial results for the,fourth ...
... Vista Partners announced today that,it has updated coverage ... Corporation (Amex: INO ). "The proposed merger of ... can create and deliver,therapeutic agents and positions Inovio/VGX, based ... arena as other gene therapy,companies," said Ross Silver, Director ...
Other Biology Technology:Inverness Medical Innovations to Present at Canaccord Adams 28th Annual Growth Conference on August 12, 2008 2PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 2PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 3PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 4PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 5PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 6PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 7PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 8PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 9PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 10PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 11PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 12PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 13PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 14Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO); $3.57 Price Target 2
(Date:3/18/2010)... , Leafcutter ant queens can live for twenty years, fertilizing ... of sexual activity. , Danish researchers who have studied ... 1992 discovered that in both ant and bee species in ... the survival of its own sperm over the other males, ...
(Date:3/18/2010)... , Boston, Mass. -- Hemangiomas -- strawberry-like birthmarks that ... but up to 10 percent cause tissue distortion or ... the 1960s, problematic hemangiomas have been treated with corticosteroids ... side effects, don,t always work, and their mechanism of ...
(Date:3/18/2010)... University of Florida engineering researchers have found they can ... say opens the door to a wave of new technologies ... about the research appears in this week,s advance online edition ... Ben Koopman and Brij Moudgil say they used lasers not ...
Breaking Biology News(10 mins):Females shut down male-male sperm competition in leafcutter ants 2Stem cells used to model infant birth defect 2Stem cells used to model infant birth defect 3Engineers: Weak laser can ignite nanoparticles, with exciting possibilities 2Engineers: Weak laser can ignite nanoparticles, with exciting possibilities 3Largest gene study of childhood IBD identifies 5 new genes 10724 1Largest gene study of childhood IBD identifies 5 new genes 10724 2American Heart Association Late Breaking Clinical Trial Report 3A Tests Predict Which Patients Are Resistant to Anti Clotting Therapy During Angioplas 61370 1American Heart Association Late Breaking Clinical Trial Report 3A Tests Predict Which Patients Are Resistant to Anti Clotting Therapy During Angioplas 61370 2American Heart Association Late Breaking Clinical Trial Report 3A Tests Predict Which Patients Are Resistant to Anti Clotting Therapy During Angioplas 61370 3Love Hormone May Trigger Jealousy Too 61369 1Love Hormone May Trigger Jealousy Too 61369 2
... in the retail nursery industry and with many home ... a variety of plants, conserve water, and reduce the ... lined with polyethylene film on the bottom and covered ... mats help minimize evaporation while allowing water to move ...
... knot have been linked to bait use of horseshoe crabs. ... weight of red knots when they leave Delaware Bay has ... crabs, has been reduced. The study also revealed that red ... population size of red knots has declined by more than ...
... new, year-long University of Pennsylvania survey of dog owners ... pets, veterinary researchers have found that most of these ... are modified. , The study, published in the current ... showed that using non-aversive or neutral training methods such ...
Other Biology News:Capillary mats labor-saving, economical alternative to hand watering 2Decline of shorebird linked to bait use of horseshoe crabs 2If you're aggressive, your dog will be too, says veterinary study at University of Pennsylvania 2